Response to Comments: MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers L39709

This document (A59875) is a response-to-comments notice related to MolDX LCD L39709 (Gene Expression Profile Tests for decision-making in castration-resistant and metastatic prostate cancers) and does not itself state coverage criteria. It provides administrative information about the comment period (8/31/2023–10/14/2023), the notice period (begins 08/08/2024), and the LCD effective date (09/22/2024). For specific coverage indications, limitations, documentation, and frequency rules, refer to LCD L39709; this response document should be reviewed alongside that LCD.